Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.9452W HIGH $72.64
Volume
413.81 K
Value Traded
21.56 M
Short % Float
13.54%
-8.99%Week
-15.36%1 Month
-12.78%3 Month
+71.77%6 Month
+38.48%5 Year
+38.48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.56 B
EPS (TTM)
-2.17
P/E Ratio
-
Ent. Value
2.15 B
Total Shares
48.16 M
Float Shares
30.50 M
Insiders
36.67%
Institutions
81.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MBX Catalyst Timeline
Dated clinical, regulatory and corporate events for MBX Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MBX Biosciences, Inc.
137Total events
8Upcoming
20Tier-1 (high impact)
2023 to 2026Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Microbix presenting and hosting one-on-one investor meetings at Cantech Investment Conference
●R&D DayPresentation
Microbix presenting at Muskoka Capital Event with 18 one-on-one investor meetings
▲Manufacturing MilestoneCMC / Inspection
Microbix completes formal supplier qualification for five major IVD manufacturers
●Equity OfferingCorporate
Inducement equity award granted to Jeff Held (89,250 options and 19,125 RSUs)
▲First Patient DosedCanvuparatideTrial
First patient dosed in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide
chronic hypoparathyroidismsource ↗
▲Trial InitiationCanvuparatideTrial
Initiation of pivotal Phase 3 oPTimize trial
chronic hypoparathyroidismsource ↗
▲Development Candidate NominationPreclinical
Nomination of MBX 6180 as GLP-1/GIP/GCG triple agonist prodrug development candidate
obesitysource ↗
●Management ChangeCorporate
Steve Hoerter appointed Chairman and CEO, John Smither appointed CFO
◆Development Candidate NominationPreclinical
Nomination of GLP-1/GIP/GCGR triple agonist candidate for obesity
obesitysource ↗
●Trial InitiationCanvuparatideTrial
Initiation of pivotal Phase 3 oPTimize trial
chronic hypoparathyroidismsource ↗
◆Oral PresentationCanvuparatidePresentation
Full results from 12-week Avail Phase 2 trial of once-weekly canvuparatide presented at ENDO 2026
chronic hypoparathyroidismsource ↗
◆Oral PresentationCanvuparatidePresentation
One-year open-label extension data from Phase 2 trial of once-weekly canvuparatide presented at 3rd Parathyroid Summit during ENDO 2026
chronic hypoparathyroidismsource ↗
◆R&D DayCanvuparatidePresentation
Virtual investor event to discuss canvuparatide presentations at ENDO 2026
chronic hypoparathyroidismsource ↗
▲Full ResultsCanvuparatideClinical Data
Full results from 12-week Avail Phase 2 trial announced
chronic hypoparathyroidismsource ↗
▲Oral PresentationCanvuparatidePresentation
Full Phase 2 and one-year OLE data presented at ENDO 2026
chronic hypoparathyroidismsource ↗
◆R&D DayPresentation
MBX Biosciences to host Obesity Day to discuss expanding obesity portfolio
obesitysource ↗
▲Topline ReadoutClinical Data
Preliminary blinded Phase 1 data for MBX 4291: mean weight loss 7% at 8 weeks in first MAD Part B cohort
obesitysource ↗
▲Development Candidate NominationPreclinical
MBX 5765 nominated as amycretin prodrug development candidate
obesitysource ↗
▲Primary Endpoint MetimapextideClinical Data
Imapextide achieved proof of concept in PBH: positive Phase 2a STEADI trial results
post-bariatric hypoglycemia (PBH)source ↗
▼Program DiscontinuationimapextideCorporate
Company will not commit further investment toward Phase 2b trial of imapextide in PBH
post-bariatric hypoglycemia (PBH)source ↗
◆R&D DayPresentation
Obesity Day featuring initial blinded data from MBX 4291 Phase 1 trial
obesitysource ↗
▲Development Candidate NominationPreclinical
Nomination of MBX 5765 as amycretin prodrug development candidate
obesitysource ↗
●Equity OfferingCorporate
Issuance of equity inducement award to new Chief Business Officer Karen Basbaum
◆Topline ReadoutimapextideClinical Data
Phase 2a STEADI trial results for imapextide
post-bariatric hypoglycemiasource ↗
◆Oral PresentationCanvuparatidePresentation
Presentation of full Phase 2 Avail trial results including OLE data at medical conference
hypoparathyroidismsource ↗
◆Development Candidate Nominationamycretin prodrugPreclinical
Nomination of amycretin prodrug development candidate
obesitysource ↗
◆Full ResultsCanvuparatideClinical Data
Full 12-week dataset and one-year follow-up data from Phase 2 Avail trial
hypoparathyroidismsource ↗
▲End Of Phase 2 MeetingCanvuparatideFDA Meeting
End-of-Phase 2 meeting with FDA completed for once-weekly canvuparatide
hypoparathyroidismsource ↗
▲EU Orphan DesignationCanvuparatideEx-US Regulatory
EU Orphan Drug Designation granted for canvuparatide
hypoparathyroidismsource ↗
▲End Of Phase 2 MeetingCanvuparatideFDA Meeting
Successful End-of-Phase 2 meeting with FDA for canvuparatide
chronic hypoparathyroidismsource ↗
▲EU Orphan DesignationCanvuparatideEx-US Regulatory
Orphan drug designation granted by EMA for canvuparatide
chronic hypoparathyroidismsource ↗
Past FDA Catalysts and PDUFA Decisions
How MBX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | canvuparatide (MBX 2109) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C49 / 100
Pipeline Score
$947M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.3x
rNPV / MCap
Top 19%
Small Cap(rank 126 of 658)
Percentile Rank
MBX Biosciences, Inc. carries a moderate pipeline score (49/100), with $1.5B risk-adjusted pipeline value, led by MBX 4291 in Obesity (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MBX 4291 Small moleculeNCT07142707 | Obesity | Phase 1 | RECRUITING | 124 | Oct 30, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every MBX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| canvuparatide Orphan | chronic hypoparathyroidism | Phase 2 | 2026-06-12 | 57% responder rate at one year; 63% of canvuparatide-treated patients achieved the primary composite endpoint at 12 weeks; 31% of placebo-treated patients achieved the primary composite endpoint at 12 weeks (p=0.042); 90% retention rate in the OLE studyRead More | MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic HypoparathyroidismRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Azoulay SalomonOfficer (Chief Medical Officer) | Sell | -370 14,399 held | $65.77 | 08/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MBX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8 % (56.9 %) | 367.19 M | 6.65 M |
MBX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MBX ranks across every disease it competes in
Competitive Position is a premium feature
See how MBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMBX News
MBX▼ -2.4%today
Microbix Making Keynote Presentation at Masters Summit 2026
Microbix Biosystems Inc. will present at the Masters Summit 2026, showcasing its successful implementation of MasterControl's electronic Quality Management System (eQMS). The presentation will detail the challenges and achievements in onboarding the software, which is crucial for becoming a qualified supplier to major life sciences companies. The event will take place in Salt Lake City, Utah, from October 12-15, 2026.
Read more →MBX▼ -2.4%today
Microbix Presenting at Cantech Investment Conference
Microbix Biosystems Inc. will present at the Cantech Investment Conference on October 8, 2026. CEO Cameron Groome will lead the presentation and hold one-on-one meetings with investors. The company, known for its contributions to diagnostic testing and laboratory quality assurance, aims to enhance global health with its innovative products. Microbix's financial performance and product offerings position it as a key player in the diagnostics industry.
Read more →MBX▼ -6.6%on this news
Microbix Presenting at Muskoka Capital Event
Microbix Biosystems Inc. will present at the Muskoka Capital Event from September 25 to 27, 2026. CEO Cameron Groome and Director Pavel Zhelev will hold 18 one-on-one meetings with investors. The company focuses on advancing global health through diagnostic products and has reported revenues of C$18.6 million for fiscal 2025.
Read more →MBXMBX Biosciences to Participate in Upcoming Investor Conferences
MBX Biosciences, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. CEO Steve Hoerter and CMO Sam Azoulay will present at the Morgan Stanley 24th Annual Global Healthcare Conference and the Stifel 2026 Virtual Cardiometabolic Forum. The company aims to showcase its pipeline of precision peptide therapies targeting endocrine and metabolic disorders.
Read more →MBXMicrobix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers
Microbix Biosystems Inc. has achieved formal qualification as a supplier for five of the largest in-vitro diagnostics manufacturers. This qualification allows Microbix to supply critical products, enhancing its business prospects. While it does not guarantee contracts, it positions Microbix favorably for future opportunities in the diagnostics market.
Read more →MBXMBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
MBX Biosciences has appointed Jeff Held as Chief Legal Officer, bringing extensive legal and executive experience from the biotechnology sector. His previous roles include leadership positions at Zenas BioPharma and Deciphera Pharmaceuticals. Held's expertise is anticipated to support MBX's growth and advancement of its precision peptide therapies for endocrine and metabolic disorders.
Read more →MBXMBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
MBX Biosciences has initiated its pivotal Phase 3 oPTimize trial for canvuparatide, a once-weekly treatment for chronic hypoparathyroidism. The trial aims to enroll around 160 adults and follows positive results from the Phase 2 Avail trial. The primary endpoint focuses on achieving normal calcium levels and reducing reliance on vitamin D supplements.
Read more →MBXMBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported its second quarter 2026 financial results, highlighting significant milestones in its pipeline. The company presented positive data for canvuparatide, a potential treatment for chronic hypoparathyroidism, and initiated a Phase 3 trial. Additionally, promising initial data for MBX 4291 supports its development as a once-monthly obesity treatment. The company maintains a strong financial outlook with substantial cash reserves.
Read more →MBX▼ -5.7%on this news
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
MBX Biosciences has announced a leadership transition, appointing Steve Hoerter as CEO and John Smither as CFO. Hoerter succeeds co-founder Kent Hawryluk, who has stepped down. The company aims to continue its growth trajectory and is on track to achieve significant milestones in 2026, including a Phase 3 trial initiation.
Read more →MBXMBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
MBX Biosciences announced positive one-year data for canvuparatide, a potential treatment for chronic hypoparathyroidism. The open-label extension study showed a 57% responder rate, consistent with previous Phase 2 results. Patients maintained normal serum calcium levels and experienced improved kidney function. The company plans to initiate a Phase 3 trial in Q3 2026.
Read more →MBXMBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
MBX Biosciences will host a virtual investor event on June 12, 2026, to discuss data on once-weekly canvuparatide. Presentations will include one-year open-label extension data and results from the 12-week Phase 2 trial at the ENDO 2026 conference. Notable experts will join the discussion, highlighting the company's advancements in peptide therapies.
Read more →MBXMBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
MBX Biosciences will present at the Jefferies 2026 Global Healthcare Conference in New York City. The presentation is scheduled for June 3, 2026, and will feature insights from CEO Kent Hawryluk and CMO Sam Azoulay. The company focuses on precision peptide therapies for endocrine and metabolic disorders and is advancing its pipeline, including candidates in various development phases.
Read more →MBXMBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences has provided an update on its obesity portfolio, highlighting preliminary Phase 1 data for MBX 4291, which shows a mean weight loss of 7% at 8 weeks. The drug was generally well tolerated, with minimal adverse events reported. The company is also advancing MBX 5765 as a new candidate and remains on track for further data releases in 2026.
Read more →MBX▲ +8.1%on this news· ran to +28% by day 1shared move
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported its first quarter 2026 financial results, highlighting advancements in its pipeline including the Phase 2 trial results of canvuparatide, which has been accepted for oral presentation at the ENDO 2026 annual meeting. The company is on track to initiate a Phase 3 trial of canvuparatide by Q3 2026 and plans to host an Obesity Day to present initial data from the Phase 1 trial of MBX 4291. With a significant cash reserve, MBX appears well positioned for future developments.
Read more →MBX▲ +8.1%on this news· ran to +28% by day 1shared move
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
MBX Biosciences has appointed Mark R. Soued as Chief Commercial Officer, bringing over two decades of experience in commercial leadership within biopharmaceuticals. His expertise includes product launches and market access, which will support MBX's commercialization efforts. The company is advancing a pipeline of precision peptide therapies targeting endocrine and metabolic disorders.
Read more →MBXMBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
MBX Biosciences will host an in-person and virtual Obesity Day on May 11, 2026, to discuss its expanding obesity portfolio. The event will feature experts Richard DiMarchi and Katherine H. Saunders, who will address treatment gaps in obesity. Management will present updates on their Precision Endocrine Peptide platform and ongoing product candidates.
Read more →MBX▼ -5.1%on this news
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MBX Biosciences has granted an equity inducement award to Karen Basbaum as she joins the company as Chief Business Officer. The award includes options for 130,000 shares at an exercise price of $32.29, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting top talent.
Read more →MBXMBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
MBX Biosciences reported its financial results for Q4 and full year 2025, highlighting significant progress in its clinical pipeline. The company is set to initiate a Phase 3 trial for canvuparatide in Q3 2026 after a successful FDA meeting. Additionally, MBX is advancing its obesity pipeline and has a strong cash position to support operations into 2029.
Read more →MBXMBX Biosciences Appoints Karen Basbaum as Chief Business Officer
MBX Biosciences has appointed Karen Basbaum as Chief Business Officer, bringing over 20 years of experience in corporate strategy and business development. Her expertise in executing high-value partnerships is expected to enhance MBX's efforts in advancing its pipeline of peptide therapies. The company focuses on addressing unmet medical needs in endocrine and metabolic disorders.
Read more →MBX▼ -5.2%on this newsshared move
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences has successfully completed an End-of-Phase 2 meeting with the FDA regarding its Phase 3 trial for canvuparatide, a treatment for chronic hypoparathyroidism. The company plans to initiate the trial in Q3 2026, with a focus on patient-centric dosing. The treatment has also received orphan drug designation in Europe, further supporting its development.
Read more →About MBX Biosciences, Inc.
Headquarters11711 N. MERIDIAN STREET, CARMEL, IN, 46032
BIOPHARMAWATCH ELITE PLUS
Trade the next MBX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime